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In this formulation study, biocompatible non steroidal anti-inflammatory (NSAIDs)-loaded 
nanoparticles were designed as models to be further integrated in a prosthesis surface 
functionalization. A modified spontaneous emulsion-solvent diffusion methodology was used to 
produce drug-loaded PLGA nanoparticles without any purification or solvent evaporation 
requirements. Formulation parameters, such as lactide/glycolide ratio, polymer concentration, 
solvent/non solvent ratio and non solvent phase, as well as the non ionic tensioactive P188 
co-precipitation composition were systematically explored. The optimized formulation (mean size: 
145 nm, surface charge: -13 mV) was employed to encapsulate various amounts of NSAIDs in a 
simple and scalable manner. The drug release was characterized in vitro by a complete release for 48 
h. These results encourage upcoming preliminary steps for in vivo experiments of prosthesis surface 
functionalization. 
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The application of polymer-based nanoparticles to exploit 
biocompatible and biodegradable polymers offers tremendous 
perspectives as therapeutic vehicles for numerous drugs 
discarded on the basis of their adverse effects. Indeed, their 
unique physicochemical properties allow improving drug 
delivery efficiency to the affected area, and sustaining 
pharmacological effects [1]. Among those drugs, non steroidal 
anti-inflammatory drugs (NSAIDs) are especially relevant to 
such a strategy considering the variety of inflammation 
pathologies. In particular, it is one of the naturally-occurring 
processes in joint or bone surgery, when a prosthesis is cemented 
into the operation site. Perioperative NSAIDs may then be 
prescribed to reduce the pain in both the short- and long-term 
surgical outcomes [2] or even to reduce the risk of postoperative 
ectopic bone formation [3, 4]. Nevertheless, the oral adminis- 
tration of NSAIDs is correlated with severe adverse gastro- 
intestinal complications and excessive wound bleedings [5, 6]. 
Nanotechnology may confer capability for prolonged and 
effective delivery of drug as a part of prosthesis surface 
functionalization.  
 Such nanoobjects, facing a complex and sensitive 
biological system as the human body, should meet manifold and 
extremely challenging requirements, such as biocompatibility, 
biodegradability, and atoxicity [7]. Furthermore, the production 
process should be simple, near-net-shape, sterile and easily 
scalable for cost-effective industrial production.  
 Following these aforementioned requirements, we aimed at 
designing NSAIDs-loaded biodegradable nanoparticles to be 
further coated onto prosthesis surface, in order to allow the local 
and controlled release of the selected NSAIDs. Poly(lactitde-co- 
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glycolide) (PLGA) has been extensively studied for drug 
delivery applications as nanoparticle matrix material because of 
its recognized biocompatibility and biodegradability [1]. Various 
methods have been designed to prepare PLGA nanospheres [1, 
7]. Among them, the Spontaneous Emulsification-Solvent 
Diffusion (SESD) method is a choice methodology since it is 
simple, low-energetic and reproducible [8]. Nevertheless, it 
generally implicates at the best class-3 residual solvents (such as 
acetone), which involves an additional purification and 
quantification step. In this preliminary formulation study, we 
aimed at optimizing this single-step, ready-to-use methodology 
with the restrained use of completely pharmaceutically-accepted 
components. A bottom-up, step-by-step strategy was applied to 
produce NSAIDs-loaded poly-(lactide-co-glycolide) (PLGA) 
nano- particles, with desirable NSAIDs payloads and release 
profile. In this respect, the process feasibility and pitfalls were 
explored through the systematic assessment of formulation 
parameters and physicochemical characterization.  
Materials and methods 
Materials 
Poly(lactide-co-glycolide) (PLGA, 50:50, 65:35, 85:15 
lactide / glycolide, molecular weights of 40-75,000, 40-75,000 
and 50-75,000 Da, respectively, as provided by the manufacturer) 
were purchased from Sigma Aldrich. Poloxamer 188 (P188, i.e. 
Pluronic®F-68, polyethyleneglycol-co-polypropyleneglycol-co- 
polyethyleneglycol), the water-miscible solvent glycofurol [9] 
(i.e. tetraglycol or tetrahydrofurfurylalcohol polyethylene glycol 
ether) and indomethacin (minimum 99% TLC) were also 
obtained from Sigma. Water was exclusively water for injections 
(Aqua B. Braun, Braun, Germany). Ibuprofen (Fagron, France) 
was of European Pharmacopeia grade. 
Preparation of PLGA nanoparticles 
PLGA nanoparticles were prepared using a modified 
spontaneous emulsification-solvent diffusion method derived 
from Niwa et al. [8]. Briefly, the specified mass of PLGA was 
dissolved in 5 mL glycofurol, in the presence of various amounts 
of NSAIDs. This organic phase was poured at a constant flow 
rate of 2 mlmin-1 to a hydrophilic phase (usually 75 ml) 
containing 0.001 % w/v poloxamer P188, magnetically stirred at 
400 rpm. Nanoparticles were spontaneously formed upon 
solvent phase diffusing into the hydrophilic phase, resulting in a 
slight blue shade (Tyndall effect). For surface modification, 
various amounts of poloxamer 188 were dissolved into the 
organic phase at the same time with the polymer and the drug, 
adopted from the methodology developed by Csaba et al. [10]. 
The rest of the experiments were conducted in a strictly similar 
way.  
Nanoparticle size and Zeta potential  
Dynamic light scattering (DLS) was used for the 
measurement of average hydrodynamic diameters and 
polydispersity indexes (PdI) (Malvern Zetasizer Nano-ZS, 
Malvern Instruments, UK). Malvern DTS v4.20 software was 
used to obtain average hydrodynamic diameters and 
polydispersity indexes (PdI) with values between 0 and 1 (a 
value of 0 means that size variation is absent, whereas a PdI 
value of 1 indicates large variations in particle size distribution). 
Each sample was analyzed in triplicate at 20°C at a scattering 
angle of 173°. 
Zeta-potential data were collected through electrophoretic 
light scattering at 25°C, 150 V, in triplicate for each sample 
(Malvern Zetasizer Nano-ZS, Malvern Instruments, UK). The 
instrument performance was checked with a Malvern-68 mV 
standard before each analysis cycle. 
Morphological studies 
The shape and surface morphology of the PLGA nano- 
particles were investigated by transmission electron microscopy 
(TEM, CM30, Philips, Limeil-Brevannes, France) at an 
accelerating voltage of 250 kV. In prior analysis, samples were 
negatively stained with 2% (w/v) uranyl acetate for 1 min.  
They were also examined by atomic force microscopy (AFM, 
Nanoscope III, Veeco, Dourdan, France) in tapping mode (scan 
rate: 1 Hz) using a silicon nitride tip with a constant spring of 46 
Nm-1 and a resonant frequency around 300 kHz. Samples were 
prepared by placing a drop of PLGA nanoparticle suspension on 
a freshly cleaved mica sheet and allowed to dry in the air. 
Experiments were performed at room temperature. To obtain Fig. 
1(c), after isolating a single nanoparticle, the AFM tip was used 
to apply a force in the middle of the nanoparticle and then, an 
image was performed in tapping mode to lower the interaction 
between the tip and the nanoparticle. 
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FIG. 1. (a) TEM photographs of nanoparticles prepared from PLGA 50:50, [PLGA] = 1.2% w/v, S/NS = 6.6% v/v. Bar: 500 nm; (b) AFM surface topography of the same 
sample obtained in tapping mode (z-scale = 300 nm); (c) 3D-AFM image of a single nanoparticle obtained after applying a force in the middle of the nanoparticle. 
NSAIDs quantification  
For drug loading measurement, NSAIDs-loaded nano- 
particle suspensions were centrifuged at 23,000 rpm and the 
suspension supernatants were quantified by HPLC. HPLC 
analyses were carried out with a C18 column (250×4.6 mm×5 
µm) mounted on a Dionex system composed of a P680 HPLC 
Pump, an ASI-100 Automated Sample Injector and a UVD340U 
detector. For ibuprofen, the mobile phase consisted of a mixture 
of acetonitrile/water 60/40 containing 1% o-phosphoric acid. 
The flow rate was 0.5 ml/min and peaks were detected as 222 nm. 
For indomethacin, the mobile phase consisted of a mixture 
methanol/water 70/30 containing 0.1% acetic acid. The flow rate 
was 1 ml/min and peaks were detected as 225 nm. Chromato- 
grams were evaluated from areas under the curve (AUC) for 
peaks with a retention time of 5.15 min for ibuprofen and 18 min 
for indomethacin. Calibration curves were performed before and 
after each quantification cycle, for ibuprofen ranging from 20 to 
20,000 ng/ml, for indomethacin from 100 to 10,000 ng/ml. 
Entrapment efficiency (EE, %) of NSAIDs and drug 
loading efficiency (DLE, % w/w) were calculated by Equations 
(1) and (2), respectively: 
 
100 (1)
mass of NSAIDs in particles
EE





mass of NSAIDs in particles
DLE
mass of re ered particles
 
 
For the drug release study, 5 ml aliquots of freshly prepared 
ibuprofen-loaded nanoparticle suspension were placed in a 
dialysis bag (Spectrum, Spectra/Por®6, MWCO=25,000 Da) 
and poured into 1 l phosphate buffer (pH=7.4) in an USP 
Dissolutest system at 37°C. The experiment was performed 
under sink condition to avoid interference from ibuprofen 
solubility in the release profile in vitro. At regular intervals, 1 ml 
of release medium was withdrawn and replaced by fresh medium 
to maintain the final volume constant. The concentration of 
released drug was measured by HPLC as described previously. 
Values were reported as the mean ± sd of four replicates. 
Results and discussion 
Prior examining and discussing the outcomes of various 
factors on the nanoparticle formation, it is important to state that 
spherical, individualized nanoparticles were obtained in a wide 
range of process conditions with fabrication yields over 90% 
(Fig. 1). TEM photographs showed a well-defined spherical 
particle shape, without noticeable aggregation (Fig. 1(a)). AFM 
images showed smooth nanoparticle surface (Fig. 1(b)). AFM 
also enabled us to precise the core-shell structure of the 
nanoparticles, as demonstrated by the possibility for the AFM tip 
to depress them upon contact (Fig. 1(c)). Nevertheless, it was not 
possible, with the use of present equipment, to quantify these 
phenomena. 
Influence of process parameters on the 
nanoparticle characteristics 
For efficient drug delivery, it is necessary that nanoparticle 
mean sizes and population polydispersity indexes should be kept 
as low as possible. In this work, hydrodynamic diameters were 
considered suitable for the potential therapeutic applications if 
mean values were less than or equal to 200 nm and 
polydispersity indexes (as calculated by the Malvern DTS v 4.20 
software) less than 0.12, which indicates monodisperse size 
distributions. Indeed mean sizes should be kept under 200 nm to 
facilitate surface prosthesis integration, for example, in a 
hydroxyapatite trabecular meshwork coating a titane surface 
prosthesis [11]. Furthermore, a constant regular drug release is 
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Table 1 Effect of some formulation parameters on sizes and zeta potentials of raw blank nanoparticles 
PLGA 
L/G ratio 






































Notes: a: P188 at a final concentration of 0.001% w/v in the NS phase; b: indicative values, means obtained on averaging several populations. S: solvent to the polymer, 
i.e. glycofurol ; NS: non solvent to the polymer, i.e. water. 
desirable for the considered therapeutic application, which can 
be reached through monodisperse size populations [12]. 
Preliminary studies on nanoparticle formation revealed that, to 
reach this goal, the critical factors during processing were 
lactide-to-glycolide ratio and polymer concentration. Other 
factors with great impacts on the final results were also examined, 
such as solvent/non-solvent volume ratio and tensioactive 
co-precipitation. Herein, solvent and non solvent refer to the 
ability to solubilize the polymer, solvent being glycofurol and 
non solvent being water, more or less enriched with tensioactive 
molecules. 
L/G ratio 
The influence of the lactide-to-glycolide (L/G) ratio on 
particle size is summarized in Table 1, for similar molecular 
weights and a fixed polymer concentration. A clear trend of 
increasing particle sizes (as well as polydispersity indexes, PdIs) 
with increasing the L/G ratio was observed. This phenomenon 
was previously reported with many types of polyester dissolved 
in a large variety of solvents, in the solvent diffusion process [13, 
14]. In fact, an increase of the L/G induces an increase of 
polymer hydrophobicity due to a higher lactide percentage. This 
would, in turn, result in increased polymer-polymer interactions, 
and consequently larger particles. Finally, a higher proportion of 
lactide units leads to a larger relative amount of crystalline 
micro-domains in its solid state [15]. When the polymer 
precipitates during desolvation, such lactide domains would 
present more difficulties to fold and re-arrange in dense spherical 
features, leading globally to bigger particles. For these reasons, 
PLGA 50:50 was selected as the most suitable polymer in this 
study. 
Polymer concentration 
As already described, polymer concentration in the solvent 
phase, and hence viscosity, greatly affects the observed sizes  
[16-18]. The mechanism of particle formation during 
spontaneous emulsification occurs according to “diffusion- 
stranding” process, also known as the Marangoni effect [18-20]. 
In this respect, the polymer concentration was varied in order to 
alter the inner solvent phase viscosity and, consequently the 
solvent diffusion rate into the non-solvent phase [17]. Contrary 
to what was generally observed [17-21], a linear response 
between polymer concentration and hydrodynamic diameters 
was not observed in this study (Fig. 2(a)). On the opposite, there 
seemed to be a critical PLGA concentration (with our protocol 
2 % w/v) above which the hydrodynamic diameters and PdIs 
were characterized by erratic values. This phenomenon was 
already observed in the case of nanoparticles produced by 
spraying PLGA-glycofurol solution into water [22]. It was as if 
the solvent molecules were being able to diffuse normally into 
the non-solvent phase until a critical polymer concentration was 
reached, which blocked the small solvent molecules into the 
folded polymer chains. This could demonstrate that the diffusion 
process is hampered by the affinity between solvent molecules 
and polymer chains, i.e. the balance between forces involved into 
polymer solvation and the ones involved into solvent diffusion, 
as stated by Choi et al. [23]. Further investigations were therefore 
conducted with a 1.5% PLGA concentration. 
Solvent/Non-solvent phases (S/NS) ratio 
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FIG. 2.  Evolution of nanoparticle sizes (hydrodynamic diameters, nm) as a function of: (a) polymer concentrations (% w/v) at constant S/NS ratio (6.6% v/v); (b) as a
function of S/NS (glycofurol/water) phase ratio (%, v/v) at constant polymer concentration (1.5 % w/v) and corresponding zeta potentials (orange points, mV); (c) as a
function of P188 / PLGA ratio (w/w) at constant polymer concentration (1.5 % w/v), before (black) and after dialysis (blue). 
Results are given as means ± sd, n = 3 to 9. 
The effect of varying the solvent (glycofurol)-to-non 
solvent (water) volume ratio (S/NS) during polymer 
precipitation was investigated, from 1 to 20 % (v/v) (Fig. 2(b)). 
Overall, for a fixed 1.5% PLGA concentration, sizes decreased 
with decreasing the S/NS ratio, until a minimum was reached 
around 7%. In our system, phase transfer was not instantaneous 
since glycofurol was more viscous than water (8-18 vs 1 mPas 
at 20°C [9]), resulting in a transient solvent concentration 
gradient into the non-solvent phase. Even if sink conditions were 
globally assumed, increasing the glycofurol/water ratio led to 
larger particles. This could be due to a locally solvent-saturated 
system at the interface, slowing down glycofurol diffusion [23] 
and therefore tending to favour nanodroplet collapses. This was 
partially visible through the evolution of zeta-potentials (Fig. 
2(b)), which were far more negative for lower ratios than higher 
ones. This testifies for the presence of glycofurol molecules 
contributing to the double solvation layer when desolvation is 
not complete. Nevertheless, for a large scale of volume ratios, 
particles remained in the range of 200 nm or less. The presence 
of a plateau in the size evolution (for glycofurol/water ratio 
smaller than 7% v/v) reveals the existence of a maximal surface 
curvature, which could not be increased whatever the ratio.  
Influence of tensioactive-polymer co-precipita- 
tion 
The development of stealth nanoparticles as drug carriers, 
which could avoid or at least reduce the uptake by phagocytes 
and therefore an immunogenic response, has been thoroughly 
examined in the last decade [24, 25]. It is now well established 
that the adsorption of blood proteins (leading to surface 
opsonisation) on hydrophilic surfaces is greatly delayed 
compared to hydrophobic ones [25]. Surface adsorption or 
polymer grafting are general methods of choice to turn an 
hydrophobic surface (such as PLGA) into a more hydrophilic 
one, using either long hydrophilic polymer chains (like 
polysaccharides or PEG) or non-ionic surfactants (for example 
PVAL, poloxamers and poloxamines). In this prospect, the 
co-precipitation approach developed by Alonso and co-workers 
is particularly interesting. They initiated a technique in which 
either poloxamines (Tetronic® 904 and 908) or poloxamers 
(Pluronic® F68 and L121) were co-dissolved in the solvent 
phase and nanoprecipitated into an aqueous phase [26]. During 
precipitation, the tensioactive molecules placed at the solvent – 
non solvent interface were trapped by physical entanglements 
with polymer chains. In this study, we applied this approach to 
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Table 2 Characterization of NSAIDs encapsulation with the optimized formulation (means of n=3, standard deviations between brackets) 





















































































a EE: encapsulation efficiency; b DLE: drug loading efficiency. 
obtain stealth nanoparticles, for which results are shown in Fig. 
2(c). 
The far less negative zeta-potentials observed on these 
particles ([-20;-30] mV), after the elimination of the tensioactive 
excess by dialysis, as compared to bare nanoparticles ([-50; -55] 
mV), is due to the presence of entrapped P188 molecules 
masking the terminal outer carboxylic charges on the PLGA 
nanoparticle surface. Increasing P188 concentration was 
performed in order to try to maximise the surface density of the 
stabilizing agent. Indeed, it has been previously reported that it 
would reduce the uptake of particles by the RES [24], without 
affecting the drug entrapment efficiency [10]. 
Sizes diminished with increasing P188 ratio in the 
glycofurol phase (Fig. 2(c)). Indeed, the more P188 molecules at 
the nanoparticle surface, the higher the hydrodynamic radius 
would appear, according to the Stockes-Einstein equation. The 
presence of the P188 tensioactive molecules, displaying a higher 
affinity for water than for glycofurol, must contribute to stabilize 
the spontaneous oil-in-water emulsion, leading to smaller 
micelle-like structures. Then upon polymer desolvation, the 
resulting solid particles present a smaller hydrodynamic diameter. 
This can happen until the limit is reached (Fig. 2(c)), limit which 
is controlled by: 1-the presence of polymer chains inside the 
nanodroplets; 2-the maximal surface curvature observed for this 
system.  
NSAIDs encapsulation 
NSAIDs-loaded nanoparticles were prepared from the 
optimized formulation, with a PLGA50:50:P188 1:1 ratio and a 
S/NS volume ratio of 6.6%. In the absence of P188 in the S 
(glycofurol) phase, total nanoparticle flocculation occurred 
between 0 and 24 h post-synthesis. In the presence of P188, the 
nanoparticle recovery yields varied with the drug concentration 
in the S phase as well as the observed sizes, while zeta-potentials 
remained globally unchanged (Table 2). Concerning the 
encapsulation efficiencies (EE) and drug loading efficiencies 
(DLE) for ibuprofen, the best compromise was obtained for a 3% 
w/v drug concentration in the solvent phase. For indomethacin, 
best results were obtained with 0.2% introduced in the S phase, 
leading to mean entrapment efficiency of 64% after dialysis and 
a similar DLE value with ibuprofen. Those data are comparable 
to those obtained by others [27-30]. 
Concerning the ibuprofen-loaded nanoparticles, the 
cumulative drug release occurred over a 2-day period and 
displayed a biphasic pattern. First, an initial burst up to 80% was 
FIG. 3. Ibuprofen release kinetics from 27%-ibuprofen loaded PLGA nano- 
particles. Mean values ± sd, n=4. 
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FIG. 4. Scheme of hypothesized ibuprofen release mechanisms: (a) state of ibuprofen (green stars) and glycofurol (yellow cones) molecules immobilized in PLGA 
(orange) and P188 (blue/orange) segments at time = 0; (b) rapid release of the surface molecules by water flow (blue arrows) in the first minutes; (c) deeper penetration 
of water molecules and subsequent slower release for times > 4 h. 
observed for 4 h (Fig. 3), corresponding to a large proportion of 
drug present at or near the nanoparticle surface (Fig. 4(a) and 
(b)). Indeed, in equivalent experimental conditions, the recovery 
of the same quantity of free ibuprofen dissolved in a blank NP 
suspension was completed in 2 h (data not shown), whereas only 
about 60% were released in the case of ibuprofen-loaded 
nanoparticles (Fig. 3). The rest (about 20%) must be located near 
the surface and then be washed out, with the adsorbed / dispersed 
part, by the water flow penetrating the polymer network (Fig. 
4(b)). It was followed by a much slower phase (Fig. 3), due to the 
entrapment of the drug deeper into the PLGA/P188 matrix (Fig. 
4(c)). As a matter of fact, to access the deeper core of the 
nanoparticle, water molecules have to create pathways and to 
exchange with solvent (glycofurol) molecules, which takes more 
time and may account for this slower release phase. The 
complete release is achieved in 48 h. 
Several factors affect the shape of the release pattern [31, 
32]. The drug release from PLGA particles may depend on three 
primary mechanisms, i.e. polymer swelling, drug diffusion 
through polymer network, and polymer degradation via 
hydrolysis [32]. For high molecular weight PLA and PLGA 
systems, the diffusion process is dominant and principally drives 
the initial burst release mechanisms [33]. The second phase is 
more generally attributed to uniform degradation and erosion of 
the particle wall, modulated through the solvent diffusion and 
subsequent enrichment of the external medium [34]. Surprisingly, 
the role of the nature and diffusion kinetics of the remaining 
solvent molecules inside the nanoparticles is scarcely discussed. 
In the case of nanocapsules, this role cannot be neglected since it 
constitutes a major component of the diffusional system. Thus, 
the remaining glycofurol molecules must contribute to plasticize 
the polymer chains and to solubilize the drug, modulating the 
NSAID release. Furthermore, this phenomenon would be 
re-enforced by the presence of PEG segments (from 
co-precipitated P188 molecules) [33], since the polymer network 
would be enlarged and facilitate drug diffusion to external 
medium. Nevertheless, the release pattern observed herein is 
comparable to what others reported about NSAIDs of the same 
chemical natures [35-37]. Indeed there seems to be a general 
finding that PLGA nanoparticles within the 200-nm range 
display a complete release less than 24 h when loaded with such 
chemicals [7]. For prosthesis surface coating, such a release 
pattern should be adequate since, occurring in a larger period 
than 24 h, it could advantageously replace an oral daily 
preventive cure.  
Conclusion 
The aim of the study was to design stealth NSAID-loaded 
polymeric nanoparticles according to a one-step nanoprecipita- 
tion process to be further coated onto prosthesis surface for drug 
controlled release. To our knowledge, the use of parenteral 
solvent glycofurol to produce PLGA-based drug delivery 
systems is scarce and mainly concerns with macro- or 
microscopic systems [38-41]. Glycofurol-based nanoparticles 
have only been reported once before this work, by spraying 
PLGA solution into water, with a lesser success in terms of 
particle production, size and drug loading efficiency [22]. 
In this work, the influence of various processing variables 
on particle characteristics was systematically assessed and the 
optimised formulation parameters were applied to a successful 
encapsulation of NSAIDs. Compared to previous reported 
approaches [27,28,30], an appreciable amount of drug was 
encapsulated and a suitable rate of drug release was achieved, 
with a complete release in 2 days, which could advantageously 
replace a daily oral administration. Preliminary in vitro assays on 
murine macrophages, presently on-going, confirm their non 
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toxicity, which opens tracks to further in vivo investigations. In 
vivo characteristics of this nanosized system should show its 
effetiveness as a part of prosthesis surface functionalisation, for 
useful NSAIDs local release. 
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